IDENTIFICATION OF A2M AS A MASTER INHIBITOR OF CARTILAGE-DEGRADING FACTORS THAT ATTENUATES THE PROGRESSION OF POSTTRAUMATIC OSTEOPATHITIS
Identification of Alpha 2 Macroglobulin (A2M) as a master inhibitor of cartilage degrading factors that attenuates post-traumatic osteoarthritis progression

Shaowei Wang, Xiaochun Wei, Jingming Zhou, Jing Zhang, Kai Li, Qian Chen, Richard Terek, Braden C. Fleming, Mary B. Goldring, Michael G. Ehrlich, Ge Zhang, and Lei Wei

Abstract

Objective—To determine if supplemental intra-articular alpha-2 macroglobulin (A2M) has a chondroprotective effect in a rat OA model.

Methods—A2M was identified as a potential therapeutic agent by comparing A2M concentrations in serum, synovial fluid (SF), and cartilage from normal and osteoarthritic (OA) patients by Western blotting, mass spectrometry, ELISA, and immunohistochemistry (IHC). The effects of A2M on IL-1-induced cartilage catabolic enzymes were evaluated by Luminex and ELISA in cultured chondrocytes. In vivo effects on cartilage degeneration and MMP-13 concentration were evaluated in male rats (N=120) randomized to four treatments: (1) CLT+saline, (2) ACLT+A2M (1IU/kg), (3) ACLT+A2M (2IU/kg) or (4) sham surgery+saline. Intra-articular injections were given for 6 weeks. The concentration of MMP-13 in SF lavages was

Disclosures: We have nothing to disclose.
measured using ELISA. OA-related gene expression was quantified by RT-qPCR. Histology was performed to grade OA.

**Results**—In both normal and OA patients, the levels of A2M were lower in SF compared to serum, and MMP-13 was higher in SF than serum of OA patients. In vitro, A2M inhibited the induction of MMP-13 by IL-1 in a dose-dependent manner in human chondrocytes. In the rat ACLT OA model, supplemental intra-articular injection of A2M reduced the concentration of MMP-13 in SF, had a favorable effect on OA-related gene expression, and attenuated OA progression.

**Conclusion**—A2M is a plasma protease inhibitor that is not present in sufficient concentrations to inactivate the high concentrations of catabolic factors found in OA SF. Our findings suggest that supplemental intra-articular A2M provides chondral protection for post traumatic OA.

**Introduction**

Anterior cruciate ligament (ACL) injury is one of the most frequent musculoskeletal injuries in adolescents and young adults, and it is known to place the injured knee at risk for early post-traumatic osteoarthritis (PTOA) (1). Evidence suggests that the current gold standard of treatment, surgical ACL reconstruction, does not appreciably reduce this risk (2–7).

Discovery of mechanisms responsible for PTOA in this patient population would enable clinicians to identify markers and targets to aid in the diagnosis, treatment, and prevention of PTOA. OA progression is due, at least in part, to the up-regulation of inflammatory mediators and proteases (8) (9–11). Since elevated levels of catabolic enzymes in synovial fluid are associated with chondrocyte death and cartilage matrix degeneration within one week of injury (8) (12) (13, 14) (15), early intervention strategies should focus on modulating these cartilage degrading enzymes within this time frame. Evidence from our group (11) (16) (17) (18) (19) and others (8) (13) (14) suggests that new molecular interventions targeting these enzymes can potentially arrest these adverse events and preserve joint health. It is unlikely however, that blocking only one of these catabolic factors would be enough to repress PTOA after injury.

Our initial hypothesis was that endogenous serum protease inhibitors are not adequately present in the joint. A2M is a serum protease inhibitor that was identified as a potential therapeutic agent by screening serum, synovial fluid (SF), and cartilage from normal and osteoarthritic (OA) patients with Western blotting, mass spectrometry, ELISA, and immunohistochemistry (IHC). A2M, a major serum protease inhibitor, inhibits all classes of endoproteases (20, 21). Our hypothesis is that A2M injected intra-articularly could potentially slow cartilage damage following a traumatic knee injury by neutralizing cartilage catabolic degrading enzymes. In order to establish a functional role for A2M in OA development, the concentrations of cartilage catabolic factors and their gene expression were quantified after A2M supplementation in cultures of human OA chondrocytes and cartilage organ cultures. The changes in cartilage catabolic enzymes were monitored in vivo by fluorescence molecular tomography (FMT) using a mouse partial medial meniscectomy (PMM) OA model. To assess the effects of A2M on cartilage damage in vivo, we used the rat ACLT model treated with supplemental intra-articular injections of A2M shortly after injury. We also characterized the endogenous expression of A2M in human knee joint...
tissues. Our results strongly indicate that A2M is a negative regulator of cartilage catabolic enzymes, but it is not present \textit{in vivo} at sufficient levels to counteract the increased concentrations of catabolic factors that appear after injury. Therefore, supplemental intra-articular injection of A2M shortly after injury may provide chondral protection to the ACL injured knee by reducing catabolic enzymes.

**Methods**

This study was approved by the IRB and IACUC at Rhode Island Hospital.

**Human samples**

OA cartilage samples were obtained from patients at the time of total joint arthroplasty (N=17, 11 female, 6 male, age 68.6±8.6 (mean±SD), range 55–79). Normal cartilage samples were obtained from patients undergoing tumor resections (N=6, 6 male, age 23.8±13.6, range 15–51). These samples were a subset of those used for a previous study (22). Serum and OA SF samples were also obtained prior to and during knee joint arthroplasty, respectively (N= 39, 20 female, 19 male, age 65.4±9.6, range 48–80) in another set of patients. OA diagnosis was made by the clinician’s assessment using American College of Rheumatology (ACR) criteria. Normal serum samples were also collected (N=43, age 37.5±10.2, range 20–56). Cartilage damage in knee joints was classified during arthroscopy before arthroscopic debridement or by direct surgical observation during joint replacement, using the Outerbridge cartilage damage score (23) (Scores 1 and 2 were designated as early stage, and Scores 3 and 4 as end stage). Normal SF samples were collected from the contralateral uninjured knees of patients undergoing unilateral ACL reconstruction, normal arthroscopy patients, and one healthy volunteer (n=33, age 26.3±11.0, range 15–54) who had no previous history of knee injury and normal standing radiographs. Human cartilage samples were divided into OA cartilage, severely fibrillated, from the more affected compartment (usually medial, Mankin score 9–14) and “relatively normal” or non-fibrillated cartilage from the uninvolved compartment (usually lateral, Mankin score 0–2) (24).

**Human serum and SF collection and analysis**

Human serum and SF samples were aliquoted and frozen at −80°C until analysis. Before performing the experiments, the SF samples were treated with 15 U/ml of bovine testicular hyaluronidase as described previously (22). The levels of A2M and MMP-13 in human serum and SF were measured by ELISA (A2M: Cat: Kt-499, Seattle, WA, USA; MMP-13: Cat: E90099Hu, USCN, Wuhan, China).

**Western blotting**

Total proteins (14μg) were separated by SDS PAGE (10% polyacrylamide) under reducing conditions, as previously reported (22). The membrane was probed with an antibody against A2M (1:1000 dilution) (sc-8513, Santa Cruz, CA). Horseradish peroxidase-conjugated secondary antibody IgG (H+L) (Bio-Rad, Hercules, CA) was diluted 1:3,000. Visualization of immunoreactive proteins was achieved by ECL (Amersham, Arlington Heights, IL). Alpha-1-antitrypsin (A1AT) was used as loading control.

\textit{Arthritis Rheumatol.} Author manuscript; available in PMC 2015 July 01.
Chondrocyte isolation and primary culture

Human chondrocytes were isolated as previously described (22) and plated either in 8-well chambers at $1 \times 10^5$ cells/well or in 6-well culture plates at $1 \times 10^6$ cells/plate. At 90% confluence, the cells were cultured overnight under serum-free conditions and then treated with recombinant human IL-1β (10ng/ml) for two hours before treatment with different concentrations of A2M protein (Sigma, St. Louis, MO). Culture medium was collected after 24 hours and analyzed for catabolic cytokines and MMPs. The same experiments were also performed using the human chondrocyte cell line, C-28/12 and cartilage tissues (25).

Luminex assay

Catabolic cytokines and MMPs in the culture medium were quantified by Luminex Human Inflammatory 5-Plex Panel (Invitrogen, Cat: LHC0003) and Luminex Human MMP 3-Plex Panel (Invitrogen, Cat: LHC6002) respectively. The inflammatory panel measured GM-CSF, IL-1β, IL-1RA, IL-6, IL-8, and TNF-α; and the MMP panel measured MMP-3, -9, and -13. The 5-Plex or 3-Plex beads were incubated with 100 μl of either standards or samples for 2 hours. Biotinylated antibodies were added and incubated for 1 hour. After washing and addition of R-phycoerythrin-labeled streptavidin, the plates were analyzed using a Luminex xMAP instrument (Luminex Technologies, Inc., Austin, TX). The concentration of MMP-13 activity in the medium was quantified by ELISA (R&D Systems, Cat: F13M00). APMA activates any potentially active forms of MMP-13 present in the sample. Since we wished to measure the endogenous levels of active, but not inactive MMP-13 in samples, we did not add APMA to the sample wells.

Mouse partial medial meniscectomy (PMM) OA model

The mouse PMM OA model was used to determine the kinetics of the expression of inflammatory mediators(26) because FMT in our facility can only be used for mice. Cathepsin is a family of proteases. The changes in cathepsin mediated inflammation in vivo were monitored by fluorescence molecular tomography (FMT) at different time points post-menisectomy (N=4).

Fluorescence Molecular Tomography (FMT)

FMT is a noninvasive and quantitative fluorescence-based technology with high molecular specificity and sensitivity for 3D tissue imaging in live animals. Biologic processes can be probed dynamically on timescales of hours to days (27, 28). ProSense™ 750-fluorescence agents become fluorescent when activated by cathepsins (Cathepsins B, L, S, and plasmin), but are optically silent in the inactivated state. Mice were injected with ProSense 750EX and imaged with the FMT system (ViSen, Waltham, MA) 24 hours after injection.

Rat ACLT OA model and treatment with supplemental intra-articular A2M injection

One hundred and twenty 10-week-old rats (180–230g) were randomized to four groups (N=30 per group): (1) ACLT + Saline, (2) ACLT + A2M(1 IU/kg), (3) ACLT + A2M(2 IU/kg) and (4) Sham + Saline. ACL transection and sham operations were performed on the right knees, as published previously (18). 1 IU/kg or 2 IU/kg of A2M (Sigma-Aldrich, St Louis, MO) dissolved in 20 μl of saline were used to treat rats in groups (2) and (3). Intr-
Articular injections were performed immediately and 3 days after ACLT, and then weekly for six weeks. Animals in groups (1) and (4) received an equivalent volume of saline at identical time points as the experimental groups (2) and (3) in their right knees to control for any procedural effects. All animals were euthanized at week 8 after the operation. Fifteen rats were used for histology study and fifteen for RT-PCR per group.

Rat SF collection and analyses

SF lavage was collected as published previously (11). MMP-13 content was measured in the SF samples by ELISA following the manufacturer’s instructions (Catalog No. E90099Ra, Uscn Life Science Inc., Wuhan, China). Colorimetric density on the developed plates was determined using a microplate reader set to 450 nm (Model BF10000, Packard Bioscience, Meridian, CT). The ELISA assay was performed in duplicate.

Real Time PCR (qPCR)

The cartilage samples were ground with a mortar and pestle under liquid nitrogen and total RNA was isolated from human and rat knee joint cartilage, using RNeasy isolation kit (Cat. No. 74704, Qiagen, Valencia, CA) (22) (22). Cartilage samples from 3 rat tibial plateaus and femur condyles were dissected with a scalpel and pooled together. Five pooled samples per group were used for this study. (N=15/group). 1μg of total RNA was reversed transcribed to cDNA using the iScript
cDNA synthesis Kit (Bio-Rad, Hercules, CA). 40 ng/ul of the resulting cDNA was used as the template to quantify the relative content of mRNA using the QuantiTect SYBR Green PCR kit (QIAGEN, Valencia, CA) with DNA Engine Opticon 2 Continuous Fluorescence Detection System (MJ Research, Waltham, MA). Human A2M forward primer - CTT TCC TTG ATG ACC CAA GCG CC, reverse primer - GTT GAA AAT AGT CAG CGA CCT; Rat Col2a1 forward primer - AAG GGA CAC CGA GGT TTC ACT GG, reverse primer - GGG CCT GTT TCT CCT GAG CGT; Rat Acan forward primer - CAG TGC GAT GCA GGC TTC GG, reverse primer - CCT CCG GCA CTC GTT GGC TG; Rat Col10a1 forward primer - CAA GGT GTC CCA GGA TTC CC, reverse primer - CAA GCG GCA TCC CAG AAA GC; Rat Mmp3 forward primer - TTG TCC TTC GAT GCA GTC AG, reverse primer - AGA CCG CCA AAA TGA AGA GA; Rat Mmp13 forward primer - GGA CCT TCT GGT TTG GGG GC T; Rat Runx2 forward primer - CCGCAGCACACGACCACCAT, reverse primer - CGC TCC GGC CCA CAA ATC TC; 18S RNA forward primer - CGG CTA CCA CAT CCA AGG AA, reverse primer - GCT GGA ATT ACC GCG GCT.

Relative transcript levels were calculated as \( x = 2^{-\Delta\Delta C_t} \), in which \( \Delta\Delta C_t = \Delta C_t - \Delta C_{18S} \), and \( \Delta C_t = C_{\text{exp}} - C_{\text{18S}} \) as previously described (22).

Histology

Gross morphological lesions on the rat femur condyles and tibia plateau (N=15/group) were visualized by Indian ink staining (29). The femurs and tibiae were hemi-sected in the mid-sagittal plane, and each half was embedded in a single block of Paraplast X-tra (Fisher, Santa Clara, CA). Blocks were trimmed to expose cartilage. Ten adjacent sections were collected at intervals of 0μm, 100 μm, and 200 μm. Two serial 6-μm thick sections from each interval were stained with Safranin O. Cartilage degradation was quantified using the OARSI grading system (30). Three independent and blinded observers scored each section,
and the scores for all of the sections cut from the medial and lateral tibial plateaus were averaged within each joint.

**Immunohistochemistry**

Immunohistochemistry was performed on all specimens after india ink staining to detect type II and type X collagen, and MMP-13 using the Histostain-SP Kit (Zymed-Invitrogen, Carlsbad, CA). The sections were digested with 5 mg/ml of hyaluronidase in PBS (Sigma-Aldrich, St Louis, MO) for 20 min. Nonspecific protein binding was blocked by incubation with a serum blocking solution (LICOR, Lincoln, NE). The sections were incubated with antibody against rat type X collagen (2 μg/ml) (EMD, Gibbstown, NJ), MMP-13 (2μg/ml) (Santa Cruz, CA) and type II collagen (2 μg/ml) (Santa Cruz, CA) respectively at 4°C overnight. Thereafter, the sections were treated sequentially with biotinylated secondary antibody and streptavidin-peroxidase conjugate, and then were developed in DAB chromogen.

To detect the distribution of A2M in human cartilage and the synovial membrane, 6 μm sections were analyzed by immunofluorescent staining with a polyclonal antibody against A2M (sc-8513, Santa Cruz, CA). The negative control sections were incubated with isotype control antibody (sc-8514-P, Santa Cruz, CA) in PBS. The sections were incubated with primary antibody at 4°C overnight. After washing, affinity-purified TRITC conjugated donkey anti-goat secondary antibody (1:500) (Jackson, West Grove, PA) was applied with Hoechst nuclear dye (0.5 mg/ml) (Pierce, Rockford, IL).

**Statistical analyses**

Analyses of variance (ANOVA) was used to compare the in vitro concentrations of A2M, cartilage catabolic factors (GM-CSF, IL-1β, IL-1RA, IL-6, IL-8, TNF-α, MMP-3, MMP-9, and MMP-13) in different groups, and the in vivo concentrations of MMP-13 and the Col2a1, Acan, Mmp3, Mmp13, Runx2, and Col10a1 mRNA levels. A two-way mixed absolute intraclass correlation coefficient (ICC) for the cartilage damage score was calculated. Follow-up pair-wise comparisons between multiple experimental groups were carried out with orthogonal contrasts using the Scheffe’s test (α=0.05) and a test of homogeneity. Adjusted p-values for the multiple comparisons were reported. Differences were considered significant at p<0.05. Statistics were performed using SPSS software (SPSS Inc, Chicago, IL).

**Results**

**Identification of A2M in human OA and normal knee synovial fluid**

An SDS-PAGE gel stained with Coomassie Blue showed a band (approximately 180 kDa) present in higher amounts in OA SF than normal knees (Figure 1A). The band was further analyzed by mass spectrometry. The top 4 candidate proteins, Alpha-2-Macroglobulin (A2M), Fibronectin, Apolipoprotein B (APOB) and Complement component 3 (C3) were chosen for further analysis. An increase in A2M was validated by Western blotting in the SF from OA patients (N=3) compared with aged-matched normal controls (N=2). Alpha-1-antitrypsin (A1AT) was used as loading control (Figure 1B) (16).
ELISA results show that the concentration of A2M is higher in OA SF (Outerbridge score 1–2, 0.302±0.04mg/ml, N=18; Outerbridge score 3–4, 0.264±0.11mg/ml, N=14) than in healthy knees (Outerbridge score 0) (0.126±0.06mg/ml, N=16). (Figure 1C). We notice that the Western analysis suggests an obvious difference of A2M concentration between OA and normal SF whereas the ELISA gives a 3-fold-difference.

**A2M is expressed in human cartilage and synovial membrane**

Immunohistochemical (IHC) staining showed positive staining of A2M in cartilage (Figure 2A-a, 2A-b) and synovium (Figure 2A-d) from OA patients and normal controls. Quantification of mRNA from human knee joints with OA indicated that A2M mRNA levels were lower in the cartilage from the involved compartment compared to the uninvolved compartment of the joint, which we called “relatively normal” (RN) cartilage, from the same patient (N= 7 patients) (Figure 2B). Our data show that A2M is synthesized by chondrocytes and synovial membrane de novo. However, OA chondrocytes appeared to have reduced ability to produce A2M compared with those in the adjacent relatively normal cartilage (Figure 2B).

**A2M in SF is lower than A2M in normal and OA serum and MMP-13 is elevated in OA SF**

We compared the protein levels of A2M in SF and serum and found that, although A2M is higher in OA compared to normal knees, the levels are much lower in SF than in serum (Figure 3A-a). We further found that A2M protein expression is opposite to the protein levels of MMP-13 in the serum and SF in OA patients (1.53±0.052mg/ml A2M in serum and 0.24±0.002mg/ml in SF, p=0.002; compared to 91.07±16.12ng/ml MMP-13 in serum and 251.01±19.23ng/ml MMP-13 in SF, p=0.007) (N=20) (Figure 3A-b).

**A2M suppresses catabolic cytokines and MMPs**

ELISA results showed that exogenous A2M inhibited the induction of MMP-13 activity by IL-1 in a dose-dependent manner in human primary OA chondrocytes (Figure 3B-a), in human OA cartilage explants (Figure 3B-b), and in a human chondrocyte cell line C-28/12 (Figure 3B-c) (25). Our data from the Luminex Human Inflammatory Panel and Luminex Human MMP Panel further demonstrated that treatment of human primary OA chondrocytes with A2M decreased protein levels of the majority of cartilage catabolic cytokines and enzymes induced by IL-1β, including IL-1β, IL-8, TNF-α, GM-CSF, MMP-3, -9, and -13 (Figure 3C). Thus, these results suggest that A2M supplementation beyond the endogenous levels may inhibit OA cartilage degradation in vivo through decreasing cartilage catabolic and inflammatory factors, in addition to inhibiting protease activity.

**A peak in joint Cathepsin/Plasmin activity occurs at day 2 in the mouse PMM OA model**

In order to determine the optimal timing for administering exogenous A2M, cathepsin was characterized in a mouse model, in which FMT data showed that the strongest joint cathepsin mediated inflammation occurs 2 days after surgery (Figure 4A). This model results in OA that can be seen by histology (Figure 4B-a) and x-ray (Figure 4B-b) after 9 weeks.
**Supplemental intra-articular A2M attenuated PTOA pathogenesis in rat ACLT model**

We found a significant decrease in OA score in the A2M-treated rats compared with the saline-treated group (Figure 5A). After treatment with A2M at both concentrations, stronger SafraninO staining, more cellularity but less chondrocyte cloning, and less fibrillation were observed than in the saline-treated groups. The cartilage in the higher A2M (2IU/kg) group had a stronger staining and more intact surface than the lower A2M (1IU/kg) group, but weaker than in the Sham + Saline control group (Figure 5B). The OARSI Histological Grading scores in both A2M groups suggested mild degeneration (14.1±0.2 and 8.8±3.9, respectively. p=0.001) (Figure 5C), while cartilage damage in the ACLT + saline group was significantly more severe (19.9±1.8. p <0.01). The cartilage in the Sham+Saline group had the least amount of damage (0.2±0.2. p <0.01). Histologic changes were evaluated at 8 weeks only. Collagen II staining in both A2M-treated groups was stronger than the ACLT + saline groups (Figure 5C-a) and showed dose dependency. In addition, there was less immunostaining for MMP-13 and type X collagen in the 2IU A2M-treated animals compared to 1IU A2M-treated animals (Figure 5D-a,b,c). Cartilage damage was associated with the change of MMP-13 in joint lavage. In the ACLT + Saline group, the MMP-13 level in joint lavage was 2450.67±789.21ng/ml, which was higher than that in the A2M (1IU/kg) (604.35±198.76ng/ml, p=0.035), A2M (2IU/kg) (464.23±110.07ng/ml, p=0.019), and Sham + Saline groups (312.52±129.13, p=0.016) (Figure 5D).

**A2M enhances matrix gene expression in cartilage**

RT-qPCR results indicated that supplemental intra-articular A2M enhanced the levels of Col2a1 and Acan mRNA, and suppressed the mRNA levels of Mmp13, Runx2, and Col10a1 in the rat ACLT model (Figure 6). Col2a1 mRNA level in the ACLT + Saline group was significantly lower than that in the ACLT + A2M (1IU/kg), ACLT + A2M(2IU/kg) and Sham+Saline groups, and there was no significant difference among the latter three groups. The Acan mRNA levels in ACLT + A2M(2IU/kg), and Sham + Saline groups were significantly higher than that in the ACLT + Saline group. In contrast, mRNA levels of Mmp3, Mmp13, Runx2, and Col10a1 in the ACLT + Saline group were the highest among the four groups. These data suggest that A2M has a chondroprotective effect in vivo by decreasing gene expression of catabolic factors and hypertrophic markers, as well as by increasing anabolic gene expression.

**Discussion**

The results of this study suggest that A2M is a powerful inhibitor for many cartilage catabolic factors that can attenuate PTOA cartilage degeneration. A2M, a major protease inhibitor, is produced by the liver, resulting in serum concentrations of 2.2 to 2.3 mg/ml. We have shown that A2M is also produced by chondrocytes and synoviocytes, although SF levels are lower than those in serum (Fig. 1 and 2). We found that higher levels of A2M are present in the sera compared to SF of normal and OA human subjects. This difference is thought to be due to the large molecular weight of A2M, which prevents it from migrating into the SF (31) (32).
Since A2M inhibits all classes of endoproteases (20, 21), it could be used to slow the development of PTOA by neutralizing cartilage catabolic factors. Studies have shown that A2M inhibits activities of ADAMTS-4,-5,-7,-12 (20, 21), MMP-13 activity (34). Thus, the protease/A2M balance may play an important role in mediating cartilage destruction by catabolic factors. We found that the concentrations of MMP-13 were 2.8-fold higher in human OA SF samples when compared with serum, but A2M levels were 7-fold lower in human OA SF samples than in serum (Fig. 3A). MMP-3 and IL-1 beta concentrations are also higher in SF of OA subjects compared to serum by a factor of approximately 10 (35) (36) (37).

We have also shown that exogenous A2M decreases these cartilage catabolic cytokines and enzymes in vitro (Fig. 3B–C). Our FMT in vivo data confirm that peak levels of the cartilage catabolic enzymes, cathepsins B, L, S, and plasmin, can be detected at day 2 after joint injury in a mouse model (Fig. 4). Since elevated levels of catabolic enzymes in SF appear to induce chondrocyte death and cartilage matrix degeneration within one week of injury (8) (12) (13, 14) (15), early intervention may be critical for preventing or minimizing the development of PTOA. Our in vivo results in a rat ACL transection (ACLT) model suggest that this is true. Early supplemental intra-articular injection of A2M reduced the level of MMP-13 in SF and attenuated the loss of cartilage proteoglycans and collagen erosion (Fig. 5 and 6). Therefore, A2M, a negative regulator of catabolic cytokines and enzymes, is likely a therapeutic candidate (20, 21). The level of A2M in normal SF is 0.126mg/mL. One inhibitor unit is equal to 0.048mg of A2M and will increase by 38% the A2M concentration assuming the rat joint contains 1 mL SF. Future studies will focus on optimizing the dosing strategy.

Recent studies have demonstrated that A2M binds a range of cytokines, such as IL1β and TNFα and also enters into cells to regulate cellular responses to other growth factors and cytokines (38) (39) (40). Although the exact mechanism by which supplemental intra-articular A2M attenuates cartilage degeneration is not clear, it is very likely that A2M acts by binding cytokines in addition to directly neutralizing enzyme activities (41) (42) (20). The relative contributions of these mechanisms will be addressed in future studies.

A limited number of studies have attempted to indirectly quantify active A2M by measuring conversion of total A2M to inactive A2M. In one study, 90% of A2M is active in plasma, however, neutrophils and free radicals can inactivate A2M. Total SF A2M is less than serum (41). During joint inflammation or sepsis, A2M becomes inactive, presumably by complexing to proteinases (41) (43). This would suggest that from a therapeutic perspective, adequate supplemental A2M would be needed to quench catabolic enzymes. We did not directly analyze SF for inactive versus active A2M since currently available reagents only recognize total A2M.

A potential limitation to this study is that surgical ACLT may not be as traumatic as an ACL injury sustained during physical activity. Bone bruises and chondral lesions frequently occur in the latter, and these concomitant injuries may also play a role in the development of PTOA. Nonetheless, the animal ACLT model has been frequently used to study OA, and mimics human OA both macroscopically and biochemically (11, 49). Minimizing local joint
inflammation until ACL reconstruction is performed may be an important preventative measure against the long-term development of PTOA. Another limitation in our study was the use of specimens from non-age-matched patients. Obtaining age-matched controls without OA is challenging for studies of human OA. Therefore, A2M analyses were performed using “relatively normal” cartilage and OA cartilage from the same patient. We recognize that the regions in which cartilage appears normal in the OA joint may not be entirely normal and this cartilage is subject to OA SF(50). However, it provides us with a reasonable benchmark for comparison, since it is tissue with minimal damage and minimizes biologic variability.

In summary, up-regulation of cartilage catabolic cytokines and enzymes is thought to be a key mechanism of cartilage damage. Thus, inhibition of these molecules will likely slow or prevent the progression of disease. Our novel data indicate that A2M is a master inhibitor of many types of cartilage-degrading enzymes, which acts not only by blocking activity, but also by decreasing gene expression and protein levels in the joint. The innate levels of A2M in SF may not be sufficient to reduce the activities of catabolic enzymes present after joint injury. In this study, supplemental intra-articular injection of A2M attenuated cartilage degeneration in the rat ACLT model, suggesting a potential novel therapy for PTOA.

Acknowledgments

The project was supported by Grant R01AR059142 from NIH/NIAMS, R01CA166089 from NIH/NIGMS, and P20RR024484 from NIH/NCRR, NSFC 81071495, 81171676 and 81201435, SXNSF 2011011042, and the Arthritis National Research Foundation (ANRF). The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. The authors gratefully acknowledge Dr. Shi Ke for help with the imaging.

References


Figure 1. A2M is elevated in OA compared to normal synovial fluid

(A) Proteins in SF were separated by SDS-PAGE (10% polyacrylamide). Staining with Coomassie Blue showed a more prominent band (~180 kDa) in OA synovial fluid compared with normal controls. OA: 64y male. Normal: 52y male, 50y male. Sequencing of this band by mass spectrometry showed that 37 of the unique peptides matched A2M. (B) Higher A2M expression in OA synovial fluid was confirmed by Western blotting. Alpha-1-antitrypsin (A1AT) was used as loading control. OA: 68y male, 68y male, 64y female. Normal: 52y male, 47y male. (C) A2M content quantified by ELISA in synovial fluid from healthy individuals (N=16), early-stage OA patients (N=18), and end-stage OA patients (N=14). **, p<0.01.
Figure 2. A2M is expressed in cartilage and synovium
Positive staining of A2M (red fluorescence) was observed in human OA cartilage (2A-a) and human OA synovium (2A-d) (N=5, age 64.8 ± 8.7(mean±SD), range55–77), normal cartilage (2A-b) and synovium (2A-e) (N=6, age 23.8±13.6(mean±SD), range 15–51), (2A-c, negative control), indicating that A2M was produced in joint tissue. (2B) Total RNA was isolated from human severely fibrillated OA cartilage (Mankin score 9–14) and the adjacent “relatively normal” cartilage (non-fibrillated cartilage) (Mankin score 0–2) from the same OA patients (N=7, age 73.7± 7.3 (mean±SD), range 58–79). Cartilage damage was evaluated using Safranin O-stained. Real time PCR results demonstrate that A2M mRNA levels were lower in OA cartilage compared to the relatively normal cartilage from the same patient. Mean±SEM. *, p<0.05.
Figure 3. A2M negatively regulates cartilage catabolic cytokines and MMPs

(A) Although A2M concentrations are higher in OA SF than in normal SF, the levels are much lower than in normal serum (Figure 3A-a) (Normal serum: N=43, age 37.5±10.2 (mean±SD), range 20–56); OA SF: N=39, age 65.4±9.6 (mean±SD), range 48–80); Normal SF (N=33, age 26.3±11.0(mean±SD), range 15–47). Higher A2M concentration and lower MMP-13 content were detected in the serum from OA patients, when compared with OA synovial fluid (same patients. N=20, age 67.0±7.1 (mean±SD), range 55–79) (Figure 3A-b).

(B) MMP-13 activity was induced by IL-1 (10 ng/ml), and inhibited by A2M in a dose-dependent manner in human OA chondrocytes (B-a). The more potent inhibition was achieved by 200nM of A2M. Similarly, IL-1-induced MMP-13 activity was reduced by A2M (200nM) treatment of human OA cartilage explants cultures (B-b) and the human chondrocytic C28/12 cells (B-c). (C) IL-1β (10 ng/ml) induced the expression of IL-8, TNF-α, GM-CSF, and MMPs, while A2M (200nM) inhibited the increase induced by IL-1 in human OA chondrocytes. Mean±SEM. *, compared with control group, p<0.05. #, compared with IL-1 group, p<0.05. Human OA chondrocytes and explants were collected from the same patients (N=5, age 65.2±8.1, range 58–79).
Figure 4. Cathepsin peaks 2 days after knee joint injury
(A) The highest levels of cathepsin activity, detected by FMT during the 9 weeks after mice were subjected to partial medial meniscectomy (PMM), were observed 2 days after surgery (A-a), indicating an early catabolic response that subsided thereafter. Data were quantified by average ROI, and are shown as intensity at each time point over the 9-week period (A-b) (N = 4). (B) Safranin O staining and quantification of histological results using the OOCHAS grading system indicated articular cartilage damage and loss of PG staining (B-a). *, p<0.05. X-ray and micro-CT (B-b) illustrated the morphological changes in the entire knee joint at 9 weeks.
Figure 5. Supplemental intra-articular A2M attenuated PTOA pathogenesis in rat ACLT model

Decreased India ink staining (A-a) and a smoother surface with stronger Safranin O staining (A-b) were detected in the articular cartilage of A2M-treated animals comparing to the untreated controls. (B) OARSI Histological Grading score (Mean±SD) indicated that the cartilage damage in the ACLT + Saline group was the most severe of all the groups, while cartilage in the Sham + Saline group had the least damage. Cartilage damage was less in the higher A2M dose than the lower dose. (C) Type II collagen expression was higher in articular cartilage in the A2M-treated and the Sham groups, compared with the untreated ACLT + Saline group. In contrast, MMP-13 and type X collagen staining was elevated in OA-damaged cartilage in the ACLT + Saline group, but stayed low in the A2M-treated and Sham groups, which is consistent with less OA damage in these groups. (D) Similar to the Sham group, A2M-treated groups had a lower MMP-13 concentration in synovial fluid than the ACLT + Saline group.
Figure 6. Supplemental intra-articular A2M inhibits catabolism and enhances anabolic metabolism in rat ACLT model

The mRNA levels of type II collagen and aggrecan were increased in the ACLT + A2M(1IU/kg) group and ACLT + A2M(2IU/kg) group compared with to the ACLT + Saline group, suggesting the positive impact of A2M on anabolic metabolism. In contrast, MMP-3, MMP-13, Runx2 and type X collagen showed the opposite pattern. These genes were expressed at a lower level in the ACLT+A2M (1IU/kg) group and ACLT+A2M (2IU/kg) group compared with the ACLT+Saline group. Mean±SEM. *, compared to the ACLT +Saline group, p<0.01.
The content provided in this white paper is intended solely for general information purposes, and is provided with the understanding that the authors and publishers are not herein engaged in rendering medical, clinical or other professional advice or services. The information in this report is intended to help health care decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Consequently, any use of this information should be done only in consultation with a qualified and licensed professional who can take into account all relevant factors and desired outcomes. The information in the following white paper was written, prepared and distributed with reasonable care and attention. However, it is possible that some information in the following white paper is incomplete, incorrect, or inapplicable to particular circumstances or conditions. We do not accept liability for direct or indirect losses resulting from using, relying or acting upon information in the following white paper.